Rossmeisl Laboratory: Collaborators

Dr. Rossmeisl and the VCNOL are proud members of the National Cancer Institute’s Comparative Brain Tumor Consortium (CBTC). Dr. Rossmeisl also serves on the CBTC steering committee.
  • John Daniel Bourland: We work with Dr. Bourland to develop stereotactic radiosurgical (Gamma Knife) protocols tailored for the treatment of brain tumors affecting dogs and cats.
  • Rafael Davalos: Working with Rafael Davalos, the inventor of irreversible electroporation (IRE), and his team, we have pioneered the use of IRE for the treatment of brain tumors.
  • Waldemar Debinski: In collaboration with the Debinski lab we have generated novel cytotoxic agents that target cell surface proteins, IL-13Rα2 and EphA2, that are expressed on the majority of canine gliomas but are not present in normal canine brain tissue.
  • Peter Dickinson: We collaborate with Dr. Dickinson on the molecular genetic characterization of canine brain tumors, and the development of convection-enhanced delivery platforms for treatment of diseases of the brain.
  • Robert Gourdie and Zhi Sheng: We collaborate with Drs. Gourdie and Sheng to define the molecular and genetic features of malignant gliomas in order to identify novel pathways that can be exploited for drug development.
  • Akiva Mintz: We work with Dr. Mintz to develop targeted diagnostic and therapeutic radiopharmaceuticals and stem cell therapeutics with applications for use in the treatment of brain cancer.
  • Christopher Rylander: With the Rylander lab, we have developed novel catheter systems to perform Convection Enhanced Delivery more precisely and efficiently. Collectively, our technical advancements are designed break down the technical barriers that have historically been associated with the CED procedure.
  • Amanda Taylor: Dr. Taylor and the VCNOL partner to develop and refine minimally invasive neurosurgical techniques and technologies, and Dr. Taylor is a co-investigator on our P01 project, "Maximizing Local Access to Glioblastoma.”
  • Scott Verbridge: Together with the Verbridge lab, we use three dimensional engineered tumor microenvirmonents as a modeling system to develop and test new treatments for brain cancer.
  • Boo Radley Foundation: The Boo Radley Foundation is a 501 (c) (3) not-for-profit corporation established to benefit humans and canines through funding canine brain cancer research and clinical trials.